Florianova Livia, Xu Bin, Traboulsi Samer, Elmansi Hazem, Tanguay Simon, Aprikian Armen, Kassouf Wassim, Brimo Fadi
Department of Pathology, McGill University Health Centre and McGill University, Glen Site, 1001 Decarie Boulevard, Montreal, QC, H4A 3J1, Canada.
Department of Urology, McGill University Health Centre and McGill University, Glen Site, 1001 Decarie Boulevard, Montreal, QC, H4A 3J1, Canada.
World J Surg Oncol. 2015 Nov 14;13:317. doi: 10.1186/s12957-015-0730-3.
RNA-binding motif protein 3 (RBM3), involved in cell survival, has paradoxically been linked to both oncogenesis as well as an increased survival in several cancers, including urothelial carcinoma (UCA).
The putative prognostic role of RBM3 was studied using cystectomy specimens with 152 invasive UCA with 35 matched metastases, 65 carcinomas in situ (CIS), 22 high-grade papillary UCAs (PAP), and 112 benign urothelium cases.
The H-score (HS, staining intensity × % of positive cells) was used for RBM3 immunoexpression. CIS showed the highest HS (mean = 140) followed by benign urothelium (mean = 97). Metastases showed higher HS than primary invasive UCA (P ≤ 0.0001), and high HS was associated with a lower pT stage (P ≤ 0.0001) and a trend toward the absence of lymphovascular invasion (LVI, P = 0.09), but not pN stage (P = 0.35) and surgical margin status (P = 0.81). Univariate analysis (UVA) of disease recurrence only showed an association between pN stage and LVI (P = 0.005 and 0.03, respectively). On UVA of mortality, pT stage was strongly associated with death (P = 0.01) while pN stage, LVI, surgical margin status, and HS were not. Multivariate analysis confirmed the lack of HS association with recurrence (P = 0.08) and death (P = 0.32).
Stronger RBM3 immunoexpression correlated with lower stage tumors and a diminished risk for LVI. However, RBM3 does not seem to carry a prognostic significance for clinical outcome (recurrence and mortality). The exact prognostic role of RBM3 in UCA is yet to be determined.
RNA结合基序蛋白3(RBM3)参与细胞存活,矛盾的是,它与包括尿路上皮癌(UCA)在内的多种癌症的肿瘤发生以及生存率提高均有关联。
使用膀胱切除标本研究RBM3的假定预后作用,标本包括152例浸润性UCA伴35例匹配转移灶、65例原位癌(CIS)、22例高级别乳头状UCA(PAP)以及112例良性尿路上皮病例。
采用H评分(HS,染色强度×阳性细胞百分比)评估RBM3免疫表达。CIS的HS最高(均值 = 140),其次是良性尿路上皮(均值 = 97)。转移灶的HS高于原发性浸润性UCA(P≤0.0001),高HS与较低的pT分期相关(P≤0.0001),且有淋巴管侵犯(LVI)缺失的趋势(P = 0.09),但与pN分期(P = 0.35)和手术切缘状态(P = 0.81)无关。疾病复发的单因素分析(UVA)仅显示pN分期与LVI之间存在关联(分别为P = 0.00 .5和0.03)。在死亡率的UVA中,pT分期与死亡密切相关(P = 0.01),而pN分期、LVI、手术切缘状态和HS则不然。多因素分析证实HS与复发(P = 0.08)和死亡(P = 0.32)缺乏关联。
更强的RBM3免疫表达与更低分期的肿瘤以及LVI风险降低相关。然而,RBM3似乎对临床结局(复发和死亡率)不具有预后意义。RBM3在UCA中的确切预后作用尚待确定。